Details for Patent: 11,090,386
✉ Email this page to a colleague
Which drugs does patent 11,090,386 protect, and when does it expire?
Patent 11,090,386 protects LENVIMA and is included in one NDA.
Protection for LENVIMA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has nineteen patent family members in eighteen countries.
Drugs Protected by US Patent 11,090,386
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,090,386
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016224583 | ⤷ Sign Up | |||
| Brazil | 112017017428 | ⤷ Sign Up | |||
| Canada | 2976325 | ⤷ Sign Up | |||
| China | 107427505 | ⤷ Sign Up | |||
| Denmark | 3263106 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
